{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000029","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-05-14T12:01:38+00:00","discovered_at":"2026-05-14T12:05:00.583021+00:00","generated_at":"2026-05-14T12:09:23.414395+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis","bullets":["Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.","R&D expenses fell 67% to $16.1M from $48.7M; transition of elritercept to Takeda and restructuring.","Cash $281.5M as of Mar 31, 2026; expected funding into first half 2028.","Takeda plans Phase 3 trial of elritercept for anemia in myelofibrosis, broadening beyond MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000029","json":"https://secwatch.observer/filing/0001664710-26-000029.json","markdown":"https://secwatch.observer/filing/0001664710-26-000029.md","text":"https://secwatch.observer/filing/0001664710-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/0001664710-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000029/kros-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:09:23.414395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}